Pages

Showing posts with label Tech Times. Show all posts
Showing posts with label Tech Times. Show all posts

Monday, 19 September 2016

Millions Of Americans Do Not Take High Blood Pressure Drugs Properly

Almost half of Medicare beneficiaries with high blood pressure do not take medications prescribed for their condition properly putting them at increased risk ...

13 September 2016, 11:23 pm EDT By Rhodi Lee Tech Times


About 5 million Americans who have high blood pressure do not take their medicines properly. Improper use of these drugs may put older adults at risk for heart disease and other unwanted health outcomes.  ( Joe Raedle | Getty Images )

Almost half of Medicare beneficiaries with high blood pressure do not take medications prescribed for their condition properly putting them at increased risk for a range of health complications.

Researchers from the U.S. Centers for Disease Control and Prevention (CDC) said that about 5 million people age 65 years and older do not manage their high blood pressure correctly and this poses concern because it can increase their risk for stroke, heart disease, kidney disease and even premature death.

In a new study published in CDC's Morbidity and Mortality Weekly Report (MMWR) on Sept. 13, Matthew Ritchey, from CDC's Division for Heart Disease and Stroke Prevention, and colleagues found that about 70 percent of adults in the U.S. who are at least 65 years old suffer from high blood pressure but almost half of these do not have their condition under control.

Researchers also found that 26.3 percent of Medicare Part D beneficiaries, which is equivalent to 4.9 million people, do not adhere to a drug regimen, which can contribute to increased likelihood for hypertension and related health conditions.

The study likewise found that the percentage of people who do not take their blood pressure medicine is higher among certain ethnic and racial groups such as Hispanics, Blacks and American Indian/Alaska Natives.

Southern U.S. states, the U.S. Virgin Islands and Puerto Rico were also found to have the highest overall rate of people who do not take their blood pressure medicine as directed.

"Although multiple factors contribute to the high proportion of uncontrolled blood pressure among persons in this age group, persons who are adherent to their antihypertensives are 45 [percent] more likely to achieve blood pressure control and have up to a 38 [percent] decreased risk for having a cardiovascular event compared with persons who are nonadherent," the researchers reported.

The study did not look at the possible reasons why many people do not adhere to their blood pressure medications but researchers have identified possible factors such as concerns over the unwanted side effects of taking these medications and complex drug regimens.

CDC director Tom Frieden, who described the findings as troubling, said that many people also have the misconception that their blood pressure is fine since they do not experience or show any symptoms.

"There's a reason hypertension is called the silent killer," Frieden said adding that many patients who have very high blood pressure feel fine until they suffer from heart attack or stroke.

http://www.techtimes.com/articles/177558/20160913/millions-of-americans-do-not-take-blood-pressure-drugs-properly.htm

Friday, 16 September 2016

Saturated Fats May Not Be That Bad After All:

Analysis Found Sugar Industry Manipulated Heart Studies 

U.S. Dietary guidelines have long recommended that Americans limit their intake of fatty food to reduce risks for heart disease and other illnesses. Findings of a new review ...

13 September 2016, 7:35 am EDT By Rhodi Lee Tech Times

Documents from the 1960s revealed why cardiovascular diseases are primarily blamed on saturated fats. The Sugar Research Foundation paid researchers to conduct studies that would downplay the role of sugar on heart disease risk.  ( Luis Ascui | Getty Images )


U.S. Dietary guidelines have long recommended that Americans limit their intake of fatty food to reduce risks for heart disease and other illnesses. Findings of a new review, however, revealed that the sugar industry may have played a role why high consumption of fats is considered as the primary driver of cardiovascular diseases.

A considerable amount of evidences now link added sugar in the diet to hypertension and cardiovascular disease, the top cause of premature death in developed countries. Warning signs about the link between sugar and heart disease though have already emerged as early as the 1950s.

In a study reported in the journal JAMA Internal Medicine on Sept. 12, researchers revealed how a sugar industry group downplayed the link between sugar and heart disease and shifted more of the blame on fat.

Researchers from the University of California San Francisco (UCSF) found publicly available documents from the 1960s that show the trade group Sugar Research Foundation known today as the Sugar Association paid Harvard scientists the equivalent of about $50,000 today to produce a review of scientific literature on sugar, fat and heart disease.

The studies that were used in the review were chosen by the sugar group. The 1967 review, which was published in the New England Journal of Medicine deemed saturated fat as the biggest cause for heart disease and minimized the link between sugar and heart health.

"Together with other recent analyses of sugar industry documents, our findings suggest the industry sponsored a research program in the 1960s and 1970s that successfully cast doubt about the hazards of sucrose while promoting fat as the dietary culprit in CHD," the researchers wrote in their study.

Another problem with the 1967 study is that its industry funding was not disclosed when it was published obscuring a significant bias. Still, it has impacted the health of millions of Americans.

The study led government agencies such as the U.S Food and Drug Administration (FDA) to structure dietary guidelines that recommend reducing fat and carbohydrates in the diet but left sugar relatively untouched.

"The literature review helped shape not only public opinion on what causes heart problems but also the scientific community's view of how to evaluate dietary risk factors for heart disease," said study researcher Cristin Kearns, from the UCSF who discovered the industry documents.

Similar industry practices persist today. Beverage company Coca-Cola, for instance, reportedly paid money to researchers to help cast its products in good light, which could potentially increase sales.

http://www.techtimes.com/articles/177360/20160913/saturated-fats-may-not-be-that-bad-after-all-analysis-found-sugar-industry-manipulated-heart-studies.htm

Sunday, 11 September 2016

iPhone 7 Specs: What's The Difference Between iPhone 7 And iPhone 7 Plus?

Apple has officially taken the wraps off one of the most-awaited smartphones of this year — the iPhone 7 and the iPhone 7 Plus. Both the Apple handsets features top-end specs, but the devices have some differences.

8 September 2016, 10:36 pm EDT By Sumit Passary Tech Times

Apple officially unveiled the iPhone 7 and the iPhone 7 Plus on Sept. 7. Both the new iPhones have great design, specs and features but they are not created equal.  ( Apple )

Apple has officially taken the wraps off one of the most-awaited smartphones of this year — the iPhone 7 and the iPhone 7 Plus. Both the Apple handsets features top-end specs, but the devices have some differences.

Screen And display

The iPhone 7 has a 4.7-inch screen with a display resolution of 1,334 x 750 pixels and 326 ppi. Just like the iPhone 6 Plus and the iPhone 6s Plus, the iPhone 7 Plus is also bigger than the iPhone 7. The bigger iPhone sports a 5.5-inch display with 1,920 x 1,080 pixels resolution at 401 ppi.

Apple has announced that the screens of both the iPhone 7 and the iPhone 7 Plus are 25 percent brighter than previous year's models.

Camera

Camera capabilities are one of the most beloved features for many smartphone customers. Apple has added a six-element lens in the new-generation iPhones, which will allow users to shoot better videos and photos in low-light conditions.

The iPhone 7 has a 12-megapixel (ƒ/1.8 lens) primary camera with optical image stabilization (OIS). The handset offers up to 5x digital zoom. The iPhone 7 also has an all-new 7-megapixel (ƒ/2.2 lens) selfie camera.

Apple has introduced a dual-camera setup in the iPhone 7 Plus. The phablet has two 12-megapixel rear-facing cameras: one wide-angle (ƒ/1.8 lens) and the other telephoto (ƒ/2.8 lens). Just like the iPhone 7, the iPhone 7 Plus also has OIS. Apple has revealed that the iPhone 7 Plus offers up to 2x optical zoom and up to 10x digital zoom.

Apple will also introduce new features to the iPhone 7 Plus cameras later this year, which will offer a better photo shooting experience to customers.

"Coming later this year, the dual 12-megapixel cameras also enable a new depth-of-field effect, using both cameras on iPhone 7 Plus to capture images, while sophisticated technology including Machine Learning separates the background from the foreground to achieve amazing portraits once possible only with DSLR cameras," says Apple.

Battery

The latest iPhone 7 and the iPhone 7 Plus have the longest battery life ever in an iPhone.
Apple does not reveal the battery size of its phones, but according to the company the iPhone 7 Plus offers up to 1 hour longer battery life than iPhone 6s Plus, while the iPhone 7 offers up to 2 hours longer battery life than iPhone 6s.

With the iPhone 7 Plus, customers can get up to 21 hours of talk time on 3G, up to 16 days of standby time, wireless audio playback time of up to 60 hours and internet use of up to 13 hours on 3G.

The smaller iPhone 7 is believed to have a smaller battery as it offers 14 hours of talk time on 3G, up to 10 days of standby time, up to 40 hours of audio playback time and up to 12 hours of internet usage on 3G.

Form Factor

The iPhone 7 measures 5.44 x 2.64 x 0.28 inches, or 138.3 x 67.1 x 7.1 millimeters. The iPhone 7 Plus, being a bigger device, measures 6.23 x 3.07 x 0.29-inches, or about 158.2 x 77.9 x 7.3 millimeters.

At 4.87 ounces, or 138 g, the iPhone 7 is also lighter than the iPhone 7 Plus that weighs 6.63 ounces, or 188 g.

Processor And RAM

Both the iPhone 7 and the iPhone 7 Plus run on Apple's new A10 Fusion chip, which makes the iPhone 7 two times faster than the iPhone 6.

Apple never mentions the RAM capacity of its iPhones. A teardown of the iPhones in the near term will confirm the RAMs of iPhone 7 and the iPhone 7 Plus. However, it is likely that the iPhone 7 comes with 2 GB of RAM while the iPhone 7 Plus with 3 GB of RAM.

Storage

Both the new iPhones will come with 32 GB, 128 GB or 256 GB internal storage options.

Operating System

The iPhone 7 and the iPhone 7 Plus will run on the company's latest iOS 10 mobile operating system.

Price And availability

The iPhone 7 will cost $649 (32 GB), $749 (128 GB) and $849 (256 GB). Customers who want to buy the iPhone 7 Plus will have to splash an extra $120 as it will be priced at $769 (32 GB), $869 (128 GB) and $969 (256 GB).

Apple will start taking pre-orders for both the iPhone 7 and the iPhone 7 Plus starting Sept. 9 and the phones will be available from the company's online store, Apple retail store, authorized Apple resellers and select carriers from Sept. 16 onward.


iPhone 7 Specs vs. iPhone 6s: Did Apple Give You Enough Reasons To Upgrade Your iPhone?

The iPhone 7 has finally been unveiled by Apple and the question on everyone's mind is, is it worth upgrading to?

Wondering how the specs and features of the latest iPhone 7 stack up against its predecessor's, the iPhone 6s? This comparison will help you ascertain if it is worth upgrading to the latest Apple flagship.  ( Stephen Lam | Getty Images )

The company claims that the latest iteration of the 4.7-inch iPhone is a stellar device.

"iPhone 7 dramatically improves the most important aspects of the iPhone experience. It introduces advanced new camera systems. The best performance and battery life ever in an iPhone. Immersive stereo speakers. The brightest, most colorful iPhone display. Splash and water resistance. And it looks every bit as powerful as it is. This is iPhone 7," says Apple.

But is it really giving us enough reasons to upgrade from the iPhone 6s? We compare the iPhone 7 and the iPhone 6s to give us a better idea.

Display

Like the iPhone 6s, the iPhone 7 also sports a 4.7-inch Retina HD screen with a resolution of 1,334 x 750 pixels and 326 ppi pixel density.

However, what has changed is that the iPhone 7 has a screen that is 25 percent brighter than that of its predecessor. Moreover, Apple asserts that the iPhone 7 offers a wider color gamut, which basically translates to more detailed photos and a richer mobile gaming experience.

Design

The major design change for the iPhone 7 is the fact that it is dust- and water-resistant unlike the iPhone 6s. The new flagship is IP67-certified, which means that it can be submerged in 1 meter (3.28 feet) of water for nearly 30 minutes.

The dimensions of the iPhone 7 and iPhone 6s are exactly the same, but what has changed is the weight. At 138 grams (4.87 ounces), the iPhone 7 is lighter than the iPhone 6s, which weighs 143 grams (5.04 ounces).

Another change in design is the removal of the headphone jack port, which gives way to the stereo speakers on the iPhone 7. The fact that the Lightning port doubles up as the port for the EarPods wins some brownie points for the iPhone 7.

Processor, RAM And GPU

The iPhone 6s houses a dual-core A9 processor and 2 GB of RAM, whereas the iPhone 7 packs in the next-gen dual-core A10 Fusion chipset and 2 GB of RAM.

Apple asserts that the A10 Fusion chipset, which will allow "console-level gaming" on the handset, is 40 percent faster than the A9 chipset. The company claims that this is the most powerful chipset it has put into a smartphone.

The GPU of the iPhone 7 also improves on the predecessor. The A10 Fusion chipset is 50 percent quicker than the A9 GPU. Moreover, per Apple, the A10 Fusion chipset also consumes less power - two-thirds of the A9's power consumption.

Storage

While the iPhone 6s was available in 16 GB, 64 GB and 128 GB storage options, Apple has changed things around for the iPhone 7. The latest iPhone will be available in 32 GB, 128 GB and 256 GB storage options.

Camera

Like the iPhone 6s, the iPhone 7 sports a 12-megapixel primary camera, but it has been completely redesigned to house a novel image sensor that is capable of wide-angle and telephoto support.

The iPhone 7 also gets OIS support, which was missing in the iPhone 6s, but available for the iPhone 6s Plus. Selfie lovers have also been kept in mind as the front-facing camera has been bumped up to 7 megapixels versus the 5 megapixels on the older-gen model.

While the iPhone 6s had a five-element lens, the iPhone 7 touts a six-element one. The 4K video recording support at 30 fps remains the same, but the iPhone 7 offers Quad-LED True Tone Flash instead of True Tone Flash on the iPhone 6s.

Battery And Bluetooth

The NFC-capable iPhone 7 will offer 2 hours longer battery support when compared to the iPhone 6s. The new smartphone supports Bluetooth 4.2 vis-à-vis the iPhone 6s' Bluetooth 4.1.

Operating System

The iPhone 7 will come with iOS 10 out of the box, but the iPhone 6s will also get updated to the latest Apple OS in the near term.

Price

The unlocked 64 GB model of the iPhone 6s was priced at $749 upon release. By comparison, the 128 GB model of the iPhone 7 is priced at $749, which is a welcome change. The 32 GB model of the iPhone 7 will cost $649 and the 256 GB variant is priced at $849.

Apple has now discontinued the 16 GB and 64 GB models of the iPhone 6s and is instead retailing a 32 GB model for $549 and a 128 GB variant for $649.

Colors

Apple has introduced two new hues for the iPhone 7 - Jet Black and Black, which are not available for the previous-gen model and could lure consumers.

The fact that the iPhone 7 is finally waterproof and boasts a faster processor and camera capabilities could be enough reason for you to upgrade from the iPhone 6s. Moreover, the lure of a new color - Jet Black or Black - as well as the stereo speakers could be the draw.

The preorders for the iPhone 7 kick off on Sept. 9 and the phone will ship from Sept. 16.

Immunity May Protect People In Southeast Asia From Mosquito-Borne Zika Virus

10 September 2016, 11:45 am EDT By Saranya Palanisamy Tech Times

A number of Zika virus cases are being reported in Southeast Asia over the past couple of weeks, of which many cases are believed to be of locally transmitted infection. Prevalence of local Zika virus strain in the region puts forth a question on the possibility of immunity against the disease. 
People living in Southeast Asia could probably be immune to Zika virus infection. Exposure to locally transmitted Zika virus strain for more than 50 years might give them the protection from the South American strain.  ( Mario Tama | Getty Images )


Zika virus was first identified in Southeast Asia in the 1960s and in the next 50 years multiple sporadic cases were reported in many countries including Thailand, Malaysia, Singapore and Cambodia. After about half a century, a potentially serious outbreak involving 300 Zika virus cases is reported in Singapore just the past two weeks.

Eventually, the Ministry of Health's National Public Health Laboratory of Singapore sequenced the first reported three Zika virus strains, two cases from Sims Drive/Aljunied Crescent cluster and one infection acquired out of the country. Analysis showed that the sequence of Zika virus strain acquired from out of the Singapore was similar to the strain found in South America.

The report said that the result is in accordance with the fact — the patient's travel to Brazil two weeks before he developed the symptoms. The other two strains from patients who did not travel to any of the countries with an ongoing infection had sequences similar to that of Zika virus that has been circulating in the region for decades.

The researchers also noted that there is currently no evidence to explain the similarities and differences between the locally transmitted strain and South American strain in terms of type or severity of the disease.

Given that Zika virus has prevailed in Southeast Asia for a long time, it makes sense to believe that people from the region could be immune to the mosquito-borne Zika virus infection.

Jamal Sam, a virologist at the University of Malaya in Kuala Lumpur, said that there is ample evidence that the Zika virus has been in Southeast Asia for quite some time. And since there is a possibility that the virus could be infecting people silently for decades, people could be immune to the virus.

Sam added that a person infected by the virus once, won't probably get it for the second time. While it seems possible, it is not yet certain how immune people are to the virus.

However, the immunity theory may or may not work, said Jasper Chan, a microbiologist at the University of Hong Kong.

"Microcephaly, Guillan-Barre and all the other concerns about Zika are still a threat to people in this region" said Chan, until it is clearly established that people are immune to the infection. "The virus could spread explosively or not. We'll have to wait and see how the story unfolds."

http://www.techtimes.com/articles/177099/20160910/immunity-may-protect-people-in-southeast-asia-from-mosquito-borne-zika-virus.htm

FDA Warns Women Against Results Of Ovarian Cancer Screening Tests

FDA issued a warning against the use of ovarian cancer screening tests such as the CA 125 test. The agency said that erroneous results may lead women to either forgo treatment or undergo unnecessary care. 

8 September 2016, 10:17 pm EDT
By Rhodi Lee Tech Times






FDA issued a warning against the use of ovarian cancer screening tests such as the CA 125 test. The agency said that erroneous results may lead women to either forgo treatment or undergo unnecessary care.  ( Heidi Blomster | Pixabay )

The U.S. Food and Drug Administration (FDA) has issued a warning on screening tests for ovarian cancer, saying women and their doctors should be cautious when making treatment decisions based on any test result because there is currently no proven method of screening ovarian cancer.

In a statement issued on Wednesday, Sept. 7, the agency said that doctors should not recommend the use of ovarian cancer screening tests because inaccurate results may cause women to either forgo crucial treatment or get unnecessary care.

The most widely used screening test in the market is the CA 125, which measures the amount of the protein CA 125 present in the blood.

Although certain cancers, which include ovarian cancer, may boost CA 125 levels in the blood, results of the test are far from foolproof since many non-cancerous conditions may also increase the level of the protein. Erroneous test results may lead healthy women to undergo unnecessary follow-up.

Findings of a 2015 study involving 200,000 women over a course of five years suggested that the test and another ovarian screening test, Abcodia's Risk of Ovarian Cancer Algorithm, or ROCA, can potentially reduce mortality from ovarian cancer by 20 percent and may further reduce it in the decade following cancer diagnosis.

Despite this, the FDA does not recommend any currently offered test to screen for the disease. In the case of CA 125 test, which is being used extensively for screening ovarian cancer, the American Cancer Society said that no major medical or professional organization has recommended the routine use of this test to screen for ovarian cancer.

The FDA in particular showed concern for those with increased risk for ovarian cancer who may opt out of taking necessary actions to reduce their likelihood of developing the disease because of results that do not show the presence of cancer.

"Do not recommend or use tests that claim to screen for ovarian cancer in the general population of women. Be aware that testing higher risk asymptomatic patients for ovarian cancer has no proven benefit and is not a substitute for preventive actions that may reduce their risk," the FDA advised physicians in its statement.

For women with increased risk for ovarian cancer, the FDA said clinicians should refer them to a genetic counselor, a gynecologic oncologist or other appropriate specialist.

The National Cancer Institute estimates that more than 22,000 women between 35 and 74 years old will be diagnosed with ovarian cancer this year.

Saturday, 10 September 2016

Larvicide Manufactured By Sumitomo, Not Zika Virus, True Cause Of Brazil's Microcephaly Outbreak: Doctors

The microcephaly outbreak in Brazil, which coincided with the spread of the Zika virus, continues to stun the world, even months after the incident was first reported.

14 February 2016, 8:58 am EST
By Alyssa Navarro Tech Times 

A group of Argentine physicians claim that the sudden microcephaly outbreak in Brazil was not caused by the Zika virus, but by a larvicide injected into the country's water supplies.  ( Mario Tama | Getty Images ) 

Pregnant women all over the world have been advised to take caution. The Zika virus infection has been linked to newborn babies with the birth defect microcephaly. This is a congenital condition in which babies are born with unusually tiny heads.

The notion, however, has recently been challenged by a group of Argentine physicians. The group suspects that the Zika virus is not to blame for the rise in microcephaly cases, but that a toxic larvicide introduced into Brazil's water supplies may be the real culprit.

Not A Coincidence?

According to the Physicians in Crop-Sprayed Towns (PCST), a chemical larvicide that produces malformations in mosquitoes was injected into Brazil's water supplies in 2014 in order to stop the development of mosquito larvae in drinking water tanks.

The chemical, which is known as Pyriproxyfen, was used in a massive government-run program tasked to control the mosquito population in the country. Pyriproxyfen is a larvicide manufactured by Sumitomo Chemical, a company associated [PDF] with Monsanto. 

However, PCST has referred to Sumitomo as a subsidiary of Monsanto.

"Malformations detected in thousands of children from pregnant women living in areas where the Brazilian state added pyriproxyfen to drinking water is not a coincidence," the PCST wrote [pdf] in the report.

For instance, the Brazilian Health Ministry had injected pyriproxyfen to reservoirs in the state of Pernambuco. In the area, the proliferation of the Aedes aegypti mosquito, which carries the Zika virus, is very high, the PCST said.

Pernambuco is also the first state in Brazil to notice the problem. The state contains 35 percent of the total microcephaly cases in the country.

The group of Argentine doctors points out that during past Zika epidemics, there have not been any cases of microcephaly linked with the virus. In fact, about 75 percent of the population in countries where Zika broke out had been infected by the mosquito-borne virus.

In countries such as Colombia where there are plenty of Zika cases, there are no records of microcephaly linked to Zika, the group said.

When the Colombian president announced that many of the country's citizens were infected with Zika but that there was not a single case of microcephaly, the allegations soon emerged. Some 3,177 pregnant women in the country were infected with Zika, but the PCST report said these women are carrying healthy fetuses or had given birth to healthy babies.

Remain Skeptical

On its website, Sumitomo Chemical says pyriproxyfen poses minimal risk to birds, fish and mammals.

However, the evidence is overwhelming. The Washington Post reported in January that after experts examined 732 cases out of 4,180 Zika-related microcephaly, more than half were not related to Zika at all. Only 270 cases were confirmed as Zika-linked microcephaly.

On top of all the suspicions, however, the World Health Organization (WHO) has been careful not to explicitly link Zika to microcephaly.

"Although a causal link between Zika infection in pregnancy and microcephaly — and I must emphasize — has not been established, the circumstantial evidence is suggestive and extremely worrisome," said WHO General Director Margaret Chan.

In the meantime, scientists are currently racing toward developing a vaccine for the mosquito-borne infection.

While there is no solid proof yet that the larvicide causes microcephaly, the local government of Grande do Sul in the southern portion of Brazil suspended the use of the chemical larvicide pyriproxyfen.

A Monsanto representative reached out to Tech Times to clarify that the company does not sell or manufacture pyriproxyfen.

"Neither Monsanto nor our products have any connection to the Zika virus or microcephaly. 
Monsanto does not manufacture or sell Pyriproxyfen. And, Monsanto does not own Sumitomo Chemical Company. It is, however,  a business partner like others in the area of crop protection," the representative said.

Pyriproxyfen manufacturer Sumitomo Chemical also released a statement to reassure that its product is safe for use.

"Pyriproxyfen, after going through extensive toxicological testing, has shown no effects on the reproductive system or nervous system in mammals, and has been approved and registered for use in the past 20 years by the authorities of around 40 countries around the world," Sumitomo said. "...despite long term and widespread use in many different settings no correlation with microcephaly has been reported."

http://www.techtimes.com/articles/133548/20160214/monsanto-larvicide-not-zika-virus-true-cause-of-brazils-microcephaly-outbreak-doctors.htm